Keywords: Novartis, First-quarter 2012 financial results, Avastin, Lucentis, Off-label use, UK

Novartis posts sharp drop in 1st-qtr profit; challenges UK off-label Avastin use

Article | 24 April 2012

Print This

Swiss drug major Novartis (NOVN: VX) has reported a sharp fall in first-quarter 2012 profits, due in part to manufacturing problems ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in